Top

Osteoporosis International

Published in:

01-08-2017 | Original Article

Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany—A retrospective analysis of real-world data

Authors: S. Dombrowski, K. Kostev, L. Jacob

Published in: Osteoporosis International | Issue 8/2017

Abstract

Summary

In type 2 diabetes patients treated in German primary care practices, the use of dipeptidyl peptidase-4 inhibitor (DPP4i) in combination with metformin was associated with a significant decrease in the risk of developing bone fractures compared to metformin monotherapy.

Introduction

The goal of this study was to analyze the impact of dipeptidyl peptidase-4 inhibitor (DPP4i) use on the risk of bone fracture in patients diagnosed with type 2 diabetes mellitus (T2DM) in Germany.

Methods

Patients with an initial prescription of metformin between 2008 and 2014 from 1262 German general practitioner practices were selected. We matched 4160 DPP4i ever users to never users (1:1) based on age, sex, diabetes duration, body mass index, index year, and physician type. The primary outcome measure was the rate of bone fractures within five years of the start of metformin or DPP-4i therapy. Time-dependent Cox regression models were used to estimate hazard ratios (HRs) for fractures as a function of the DPP4i therapy.

Results

The mean age among the patients was 61.6 years (SD = 11.1 years), 59.6% were men, and 3.1% were followed in diabetologist practices. The mean diabetes duration was 1.5 years (SD = 2.4 years), HbA1c levels were 7.1% in DPP4i users and 6.6% in non-users, and body mass index was 31.5 kg/m² (SD = 5.0 kg/m²). Within five years of the index date, 6.4% of users and 8.3% of non-users developed bone fractures (log-rank p-value < 0.001). Within five years of the index date, 7.4% of female and 4.7% of male users and 13.3% of female and 8.8% of male non-users were diagnosed with bone fractures (both log-rank p-values < 0.001). The use of DPP4i was associated with a significant decrease in the risk of developing bone fractures (all patients HR = 0.67, 95% CI 0.54–0.84; women HR = 0.72, 95% CI 0.54–0.97; men HR = 0.62, 95% CI 0.44–0.88).

Conclusion

DPP4i use was associated with a decrease in the risk of bone fracture.

Diabetes: facts and figures. Int. Diabetes Fed. 2015. Accessed 3 March 2017. Available at: http://www.idf.org/about-diabetes/facts-figures

Germany. Int. Diabetes Fed. 2015. Accessed 3 March 2017. Available at: http://www.idf.org/membership/eur/germany

Tuominen JT, Impivaara O, Puukka P, Rönnemaa T (1999) Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 22:1196–1200CrossRefPubMed

Vestergaard P: Bone metabolism in type 2 diabetes and role of thiazolidinediones. Curr Opin Endocrinol Diabetes Obes 2009, 16:125–131. [doi: 10.1097/MED.0b013e328325d155]

Mamza J, Marlin C, Wang C, Chokkalingam K, Idris I (2016) DPP-4 inhibitor therapy and bone fractures in people with type 2 diabetes—a systematic review and meta-analysis. Diabetes Res Clin Pract 116:288–298. doi:10.1016/j.diabres.2016.04.029 CrossRefPubMed

Wallace C, Reiber GE, LeMaster J, Smith DG, Sullivan K, Hayes S, Vath C (2002) Incidence of falls, risk factors for falls, and fall-related fractures in individuals with diabetes and a prior foot ulcer. Diabetes Care 25:1983–1986CrossRefPubMed

Carnevale V, Romagnoli E, D’Erasmo E (2004) Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 20:196–204. doi:10.1002/dmrr.449 CrossRefPubMed

Montagnani A, Gonnelli S (2013) Antidiabetic therapy effects on bone metabolism and fracture risk. Diabetes Obes Metab 15:784–791. doi:10.1111/dom.12077 CrossRefPubMed

Monami M, Dicembrini I, Antenore A, Mannucci E (2011) Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 34:2474–2476. doi:10.2337/dc11-1099 CrossRefPubMedPubMedCentral

10.

Fu J, Zhu J, Hao Y, Guo C, Zhou Z (2016) Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. Sci Rep 6:29104. doi:10.1038/srep29104 CrossRefPubMedPubMedCentral

11.

Driessen JHM, van den Bergh JPW, van Onzenoort HAW, Henry RMA, Leufkens HGM, de Vries F (2016) Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture; a retrospective population-based cohort study. Diabetes Obes Metab. doi:10.1111/dom.12843 PubMed

12.

Becher H, Kostev K, Schröder-Bernhardi D (2009) Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 47:617–626CrossRefPubMed

13.

Kyvernitakis I, Kostev K, Kurth A, Albert US, Hadji P (2014) Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 25:2721–2728. doi:10.1007/s00198-014-2810-6 CrossRef

14.

Jacob L, Dreher M, Kostev K, Hadji P (2016) Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 27:963–969. doi:10.1007/s00198-015-3378-5 CrossRef

15.

Kyvernitakis I, Kostev K, Nassour T, Thomasius F, Hadji P (2017) The impact of depot medroxyprogesterone acetate on fracture risk: a case–control study from the UK. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 28:291–297. doi:10.1007/s00198-016-3714-4 CrossRef

16.

Allison PD (2010) Survival analysis using SAS: a practical guide, 2nd edn. SAS Institute, Cary

17.

Majima T, Komatsu Y, Yamada T, Koike Y, Shigemoto M, Takagi C, Hatanaka I, Nakao K (2005) Decreased bone mineral density at the distal radius, but not at the lumbar spine or the femoral neck, in Japanese type 2 diabetic patients. Osteoporos Int 16:907–913. doi:10.1007/s00198-004-1786-z CrossRefPubMed

18.

Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int 18:427–444. doi:10.1007/s00198-006-0253-4 CrossRefPubMed

19.

Rathmann W, Kostev K (2015) Fracture risk in patients with newly diagnosed type 2 diabetes: a retrospective database analysis in primary care. J Diabetes Complicat 29:766–770. doi:10.1016/j.jdiacomp.2015.05.007 CrossRefPubMed

20.

Pscherer S, Kostev K, Dippel FW, Rathmann W (2016) Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care. Diabetes Metab Syndr Obes Targets Ther 9:17–23. doi:10.2147/DMSO.S101370

21.

Molinuevo MS, Schurman L, McCarthy AD, Cortizo AM, Tolosa MJ, Gangoiti MV, Arnol V, Sedlinsky C (2010) Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res Off J Am Soc Bone Miner Res 25:211–221. doi:10.1359/jbmr.090732 CrossRef

22.

Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N (2008) The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 149:574–579. doi:10.1210/en.2007-1292 CrossRefPubMed

23.

Nuche-Berenguer B, Moreno P, Esbrit P, Dapía S, Caeiro JR, Cancelas J, Haro-Mora JJ, Villanueva-Peñacarrillo ML (2009) Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int 84:453. doi:10.1007/s00223-009-9220-3 CrossRefPubMed

24.

Janssen P, Rotondo A, Mulé F, Tack J (2013) Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther 37:18–36. doi:10.1111/apt.12092 CrossRefPubMed

25.

Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ, Christiansen C (2009) Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 45:833–842. doi:10.1016/j.bone.2009.07.008 CrossRefPubMed

26.

Schwartz AV, Vittinghoff E, Sellmeyer DE, Feingold KR, de Rekeneire N, Strotmeyer ES, Shorr RI, Vinik AI, Odden MC, Park SW et al (2008) Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care 31:391–396. doi:10.2337/dc07-1152 CrossRefPubMed

27.

Kim J-H, Jung M-H, Lee J-M, Son H-S, Cha B-Y, Chang S-A (2012) Diabetic peripheral neuropathy is highly associated with nontraumatic fractures in Korean patients with type 2 diabetes mellitus. Clin Endocrinol 77:51–55. doi:10.1111/j.1365-2265.2011.04222.x CrossRef

Title: Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany—A retrospective analysis of real-world data
Authors: S. Dombrowski
K. Kostev
L. Jacob
Publication date: 01-08-2017
Publisher: Springer London
Published in: Osteoporosis International / Issue 8/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-017-4051-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany—A retrospective analysis of real-world data

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2017

Oral contraceptive use and fracture risk—a retrospective study of 12,970 women in the UK

Vibrational spectroscopic techniques to assess bone quality

Increased blood cadmium levels were not associated with increased fracture risk but with increased total mortality in women: the Malmö Diet and Cancer Study

A translational approach from an animal model identifies CD80 as a candidate gene for the study of bone phenotypes in postmenopausal women

Comparison of total, free and bioavailable 25-OH vitamin D determinations to evaluate its biological activity in healthy adults: the LabOscat study

Circulating periostin levels increase in association with bone density loss and healing progression during the early phase of hip fracture in Chinese older women